[18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia. A decade of studies

J M Hoffman; B H Guze; L R Baxter; J C Mazziotta; M E Phelps

doi:10.1159/000116476

[18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia. A decade of studies

Eur Neurol. 1989:29 Suppl 3:16-24. doi: 10.1159/000116476.

Authors

J M Hoffman¹, B H Guze, L R Baxter, J C Mazziotta, M E Phelps

Affiliation

¹ Department of Radiological Sciences, University of California, Los Angeles.

PMID: 2693102
DOI: 10.1159/000116476

Abstract

Alzheimer's disease (AD) is becoming an increasingly important public health problem. The clinical diagnosis of AD continues to be problematic and costly. [18F]-fluorodeoxyglucose-position emission tomography (FDG-PET) can assist with the diagnosis of AD at an early stage. The utility of FDG-PET in AD may also be extremely useful in the future when objective physiologic monitoring of drug effects and therapy are required.

Publication types

Review

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Aging / metabolism*
Alzheimer Disease / diagnostic imaging*
Alzheimer Disease / metabolism
Child
Deoxy Sugars*
Deoxyglucose* / analogs & derivatives
Deoxyglucose* / pharmacokinetics
Female
Fluorodeoxyglucose F18
Humans
Male
Middle Aged
Radionuclide Imaging

Substances

Deoxy Sugars
Fluorodeoxyglucose F18
Deoxyglucose